How is Wegovy dosed?

What Wegovy is

Wegovy is a brand name. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The label states Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, or in adults with overweight and at least one weight-related comorbid condition; and, under accelerated approval, for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults. The same label also covers a separate oral tablet formulation, indicated for cardiovascular risk reduction and weight reduction in adults — the label’s own revision history shows both its Indications and Usage and Dosage and Administration sections were revised in December 2025, consistent with trade-press reports of a December 22, 2025 approval for the tablet. The tablet is dosed differently from the injection; both schedules are read below.

Semaglutide is also sold under other brand names, at different doses, for different indications — Ozempic (type 2 diabetes) and Rybelsus (an oral form, type 2 diabetes only) are the same molecule with different labels. The Prof. Peptide semaglutide profile covers how the three relate, the mechanism, and the published trial evidence across all of them. This page reads Wegovy’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Ozempic’s or Rybelsus’s.

What the label specifies

Both schedules below come from the same document — Novo Nordisk, WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective June 18, 2026.

Wegovy injection

The table below is Wegovy injection’s recommended dosage as stated in sections 2.1 and 2.2 of the label.

Section 2.4 states that if a dose of Wegovy injection is missed and the next scheduled dose is more than 2 days away, the label instructs administering it as soon as possible; if less than 2 days away, the label instructs skipping the missed dose and resuming the regular schedule. If 2 or more consecutive doses are missed, the label instructs reinitiating dosage escalation at a lower dosage. This window is shorter than Ozempic’s label, which allows 5 days before a missed dose is skipped.

Dosage forms and strengths (section 3) list single-dose pens and prefilled syringes at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg per injection — the label’s strengths are per-injection figures from a pre-filled pen. The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

Wegovy tablets (oral)

The table below is Wegovy tablets’ recommended dosage as stated in section 2.3 of the label, for cardiovascular risk reduction or weight reduction in adults.

The label instructs taking Wegovy tablets orally once daily on an empty stomach in the morning with up to 4 ounces of plain water only, swallowing the tablet whole (not split, crushed, chewed, or dissolved), and waiting at least 30 minutes after taking it before eating food, drinking any other beverage, or taking other oral medications. If patients do not tolerate the 25 mg maintenance dosage, the label states to consider switching to Wegovy 1.7 mg injection.

Section 2.4 states a different missed-dose rule for the tablet than for the injection: if a dose of Wegovy tablets is missed, the label instructs skipping the missed dose and taking the next dose the following day — there is no days-away calculation, unlike the injection’s 2-day rule above.

Section 2.5 (Switching Between Wegovy Injection and Wegovy Tablets) states that patients taking Wegovy 2.4 mg injection may switch to Wegovy 25 mg tablets one week after discontinuing the injection, initiating the tablet directly at the 25 mg maintenance dosage without repeating the escalation. Patients switching the other direction, from Wegovy 25 mg tablets to injection, initiate Wegovy 2.4 mg subcutaneous injection the day after discontinuing the tablet, again without repeating the injection’s own escalation.

Dosage forms and strengths (section 3) list tablets at 1.5 mg, 4 mg, 9 mg, and 25 mg — distinct strengths from the injection’s per-pen figures above, and not interchangeable milligram-for-milligram given the tablet’s low oral bioavailability.

What the trials administered

Section 14 of the label (Clinical Studies) names Wegovy’s trials as “Study 1” through “Study 10,” each with its own NCT registry number — the label never uses the word “STEP” (confirmed by a direct search of the label text; the only “step” occurrences are injection-technique instructions). “STEP” is the separately-published, publicly known name for the weight-reduction trial program; it is noted once below for the reader’s benefit but the citation itself follows the label’s own naming. The three trials below are the ones underlying the dosing and outcomes discussed on this page — two for the injection, and Study 7 for the tablet. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source. All three grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.

Ozempic’s label cites a different trial program (the monotherapy trial, SUSTAIN 6, and FLOW) at different doses and different indications. Those figures belong to Ozempic’s own label, not Wegovy’s, even though both products share the same active ingredient — the semaglutide profile covers the trial evidence across brands directly.

The label’s warnings and adverse events

Table 3 of the label reports adverse reaction rates (≥2% and greater than placebo) among adults treated with the 2.4 mg maintenance dosage for weight reduction:

For Wegovy tablets, the label states that adverse-reaction types and frequencies in Study 7 were similar to those in the injection table above, rather than reporting a separate per-reaction breakdown. It does report tablet-specific discontinuation figures: 6.9% of Study 7 participants treated with Wegovy 25 mg tablets permanently discontinued treatment due to adverse reactions, versus 5.9% on placebo; the most common reason was gastrointestinal adverse reactions, reported in 3.4% of tablet-treated participants versus 2% on placebo.

Compounding and research-grade semaglutide

Separately from the branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.

On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.

None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded semaglutide is itself unsettled and separate from both.

How this page differs from Ozempic’s and the semaglutide profile

Wegovy and Ozempic share an active ingredient but not a label. Ozempic’s three indications are glycemic control, cardiovascular risk reduction, and chronic kidney disease risk reduction in adults with type 2 diabetes, capped at 2 mg once weekly, with a 5-day missed-dose window and a single injectable dosage form. Wegovy’s three indications are cardiovascular risk reduction, weight reduction, and noncirrhotic MASH — none of them require type 2 diabetes — escalating to as high as 7.2 mg once weekly for weight reduction, with a shorter 2-day missed-dose window, and a second oral tablet formulation the injectable label doesn’t have. The two labels cite entirely separate trial programs: Ozempic’s monotherapy trial, SUSTAIN 6, and FLOW versus Wegovy’s Study 1, Study 2, and Study 7 above.

The semaglutide profile is a different kind of page: it covers the molecule’s mechanism and the published trial evidence across all semaglutide brands at once, without reading any single FDA label’s escalation schedule, boxed warning, or adverse-event table in the detail this page does. This page exists because Wegovy’s own prescribing information has figures — the missed-dose window, the maintenance dosage options, the ADR percentages at the 2.4 mg dose — that the profile doesn’t report and that only Wegovy’s own label states.

FAQ

References

1. Novo Nordisk. WEGOVY (semaglutide) injection and tablets — prescribing information. DailyMed, setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
3. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
4. ClinicalTrials.gov. Research Study on Heart Disease in People With Overweight or Obesity (SELECT), NCT03574597. https://clinicaltrials.gov/study/NCT03574597
5. ClinicalTrials.gov. Research Study on the Long-term Effects of Semaglutide in Participants With Overweight or Obesity (STEP 1), NCT03548935. https://clinicaltrials.gov/study/NCT03548935
6. ClinicalTrials.gov. Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (Study 7), NCT05564117. https://clinicaltrials.gov/study/NCT05564117